Preclinical studies have highlighted the potential of prenatal molecular chaperone treatment (65), and a trial is underway to evaluate DITPA treatment of affected children in utero to determine if treating MCT8 deficiency before birth has a positive impact on fetal neurodevelopment (51). This evidence concerns the gene SLC16A2 and hyperinsulinemic hypoglycemia, familial, 4.